1 Do smoking and alcohol behaviours influence risk of type 2 diabetes? A Mendelian

2 randomisation study.

- 3 Short title: Mendelian randomisation of smoking, alcohol and type 2 diabetes
- 4 Zoe E. Reed^{1,2}, Hannah M. Sallis^{2,3,4}, Rebecca C. Richmond^{2,3}, Angela S. Attwood^{1,2}, Deborah
- 5 A. Lawlor^{2,3}, Marcus R. Munafò^{1,2,5}
- 6 1 School of Psychological Science, University of Bristol, Bristol, UK
- 7 2 MRC Integrative Epidemiology Unit at the University of Bristol, Bristol, UK
- 8 3 Population Health Sciences, Bristol Medical School, University of Bristol, Bristol, UK
- 9 4 Centre for Academic Mental Health, Bristol Medical School, University of Bristol, Bristol,
- 10 UK
- 11 5 National Institute for Health Research Bristol Biomedical Research Centre, University
- 12 Hospitals Bristol NHS Foundation Trust and University of Bristol, Bristol, UK
- 13 Corresponding author: Zoe Reed, <u>zoe.reed@bristol.ac.uk</u>

NOTE: This preprint reports new research that has not been certified by peer review and should not be used to guide clinical practice.

14 Abstract

15	Background: Previous studies suggest that smoking and higher alcohol consumption are
16	both associated with greater risk of type 2 diabetes (T2D). However, studies examining
17	whether these associations reflect causal relationships are limited and do not consider
18	continuous glycaemic traits. The aim of the study was to determine whether there are
19	causal effects of smoking and alcohol consumption on T2D risk and related glycaemic traits.
20	Methods and Findings: We conducted both two-sample and one-sample MR to examine the
21	effects of lifetime smoking index (LSI) and alcoholic drinks per week on T2D and continuous
22	traits (fasting glucose, fasting insulin and glycated haemoglobin, HbA1c). For two-sample
23	MR we used results from genome-wide association studies (GWAS) of LSI (N=462,690),
24	alcohol consumption (N=941,280), T2D (N= 148,726 cases and 965,732 controls) and
25	continuous traits (N=149,289 to 209,605). We used inverse variance weighting (IVW) for our
26	main analyses and conducted several sensitivity analyses to explore violation of MR
27	assumptions. We compared two-sample MR to one-sample MR results for alcohol effects on
28	T2D and HbA1c in UK Biobank (N=336,984). Only these analyses were conducted to avoid
29	sample overlap and due to data availability. The main IVW two-sample MR results suggested
30	possible causal effects of higher LSI on T2D risk (OR per 1SD higher LSI=1.42, 95% CI=1.22 to
31	1.64); however, sensitivity analyses did not consistently support this finding, and there was
32	evidence of potential horizontal pleiotropy. There was no robust evidence that higher drinks
33	per week influenced risk of T2D from our main IVW two-sample MR analyses (OR per 1 SD
34	higher log-transformed drinks per week=1.04, 95% CI=0.40 to 2.65), despite evidence of
35	causal effects on higher fasting glucose (difference in mean fasting glucose in mmol/l per
36	1SD higher log-transformed drinks per week=0.34, 95% CI=0.09 to 0.59). One-sample MR

37	results suggested a possible causal effect of higher drinks per week on T2D risk (OR per 1 SD
38	higher log-transformed drinks per week=1.71, 95% CI: 1.24 to 2.36), but in contrast, lower
39	HbA1c levels (difference in mean SD of log transformed HbA1c (mol/mol) per 1 SD higher
40	log-transformed drinks per week=-0.07, 95% CI: -0.11 to -0.02). Key limitations include
41	limited generalisability of results due to analyses being conducted in European populations,
42	and potential selection bias in UK Biobank influencing results.
43	Conclusion: Our results suggest effective public health interventions to prevent and/or
44	reduce smoking and alcohol consumption are unlikely to reduce the prevalence of T2D.
45	Keywords: type 2 diabetes, alcohol, smoking, Mendelian randomisation, UK Biobank,

- 46 glycaemic traits.
- 47

48 Introduction

49	Type 2 diabetes (T2D) is a common chronic condition that is known to increase risk of
50	macro- and micro- vascular atherosclerotic diseases (1–4). Over the last 30 years,
51	prevalence and incidence of T2D has increased markedly (5), and the age at which it is first
52	diagnosed has decreased (6). These changes are largely thought to be driven by the global
53	obesity epidemic (7), including increased testing for T2D in people who are obese. Whilst
54	higher body mass index (BMI) is an established causal risk factor for T2D (8), other risk
55	factors have been proposed.
56	Both smoking and alcohol have been suggested as notential risk factors that may causally
50	beth shroking and alcohor have been suggested as potential risk factors that may eausary
57	affect T2D. Observationally, smoking is associated with higher risk, with heavier smokers
58	having the greatest risk (9–12). Additionally, former smokers seem to have a higher risk for
59	T2D compared to never smokers, with risk lowering over time since they quit (10,13). For
60	alcohol consumption, there is a long history of observational studies suggesting a J-shaped
61	association with cardiovascular diseases (14–16), with some studies finding evidence of a
62	similar pattern with T2D (17,18). This slightly higher risk among those who report no alcohol
63	consumption may be an artefact, for example due to misreporting, or because some people
64	stop drinking (or never start) for health reasons (11,19). Despite this apparently higher risk
65	at lower levels, across most of the distribution, higher alcohol consumption is associated
66	with higher risk for T2D. The associations of smoking and alcohol with T2D might be causal
67	or they might be influenced by confounding due to limited adjustment for socioeconomic
68	position and related factors or only partially accounting for these in previous studies. In this
69	study we aim to determine whether the relationships between smoking and alcohol and
70	T2D are causal.

- 71 Mendelian randomisation (MR) is a causal inference method, which commonly uses genetic
- variants, typically single nucleotide polymorphisms (SNPs), as instrumental variables (IVs)
- 73 for the exposure of interest. MR is less prone to confounding by socioeconomic,
- 74 environmental and behavioural characteristics, or reverse causation than conventional
- 75 observational studies (20). It can be biased by violation of the core assumptions underlying
- 76 MR (Box 1).

Box 1. Core assumptions of Mendelian Randomisation

1) The genetic IV is robustly associated with the exposure of interest in the relevant population (relevance). May cause biased results if there are weak instruments (i.e., a statistically weak association of the genetic instrument with the exposure, which would bias results towards the null in two-sample MR and towards the confounded association in one-sample MR. In this study, comparing results from two- and one-sample MR for some effects is useful as, if both give consistent results this gives us greater confidence that neither have weak instrument bias. Population relevance is particularly important in two-sample MR, where it is important to ensure that the underlying population is the same in both samples and consistent with the population that we want to make inference to. Therefore, in this study we restricted analyses to include results from the genetic instrument-exposure and genetic instrument-outcome associations in white European adult populations only.

2) There is no confounding between the genetic IV and the outcome (independence).

May be violated if there is population stratification, assortative mating, or confounding by dynastic factors. In this study we tried to minimise population stratification by only including results / data from participants of European ancestry and adjusting for principal components in our one-sample MR analyses.

3) The genetic IV is only associated with the outcome via the exposure, and there are no direct effects of the genetic IV on the outcome (**exclusion restriction**).

May be violated if there is horizontal pleiotropy (i.e. the genetic variants influence risk factors for the outcome, independently of the exposure of interest. In this study we explored the likelihood of unbalanced horizontal pleiotropy influencing our main two-sample MR IVW results through comparing those results to results from several pleiotropy robust sensitivity analyses.

77

Two previous two-sample MR studies have found evidence for a potential causal effect of
smoking initiation (21) and lifetime smoking (22) on risk of T2D. The former study used data
from a genome wide association study (GWAS) of diabetes with 74,124 cases and 824,006

controls and focused on smoking initiation, which does not capture other important
smoking related behaviours, like smoking duration and intensity. The latter study used data
from the same diabetes GWAS and was an atlas study that examined many outcomes, and
therefore did not focus on this relationship, nor did it consider continuous traits related to
diabetes.

86 We identified two previous MR studies examining alcohol and T2D. The first reported no 87 effect. It used one SNP from the alcohol dehydrogenase 1B gene which encodes an enzyme involved in alcohol metabolism (i.e., it directly influences the amount of alcohol consumed 88 89 in those who have ever drunk alcohol), in a one-sample MR approach within 261,991 adults 90 of European ancestry (with 14,549 cases) (23). This is a useful approach as there is unlikely 91 to be bias due to horizontal pleiotropy. Therefore, further exploration, using two-sample 92 MR and exploring underlying continuous traits may strengthen the conclusion of no effect, if 93 results were consistent. The second study also used a one-sample MR approach and a 94 genetic risk score for alcohol within UK Biobank (UKBB) (N=408,540 with 33,656 cases) and 95 found a potential causal effect of higher alcohol intake on T2D risk, with the strongest 96 effects found in heavier drinkers in analyses stratified by alcohol intake (24). Our study 97 extends this work by including continuous traits related to diabetes and examining this 98 within a two-sample MR approach as well.

99 The aim of this study was to use MR to explore the effects of lifetime smoking and alcohol 100 consumption (drinks per week) on T2D risk and underlying glycaemic traits. This adds to 101 previous studies by exploring both T2D and related continuous traits, exploring effects of 102 both smoking and alcohol behaviours in the same study, undertaking more sensitivity 103 analyses to test genetic instrument validity, and the influence of unbalanced horizontal

- 104 pleiotropy on our results, and comparing results from our main two-sample MR with those
- 105 from one-sample MR, where this was possible, and data was available. In this study we used
- 106 lifetime smoking as one exposure as this can be applied to non-smokers (unlike smoking
- 107 heaviness) too and allows for a richer phenotype incorporating a range of smoking
- 108 behaviours. We used alcohol consumption as our other exposure (i.e., average number of
- 109 drinks participants reported consuming each week across all types of alcohol) to capture
- 110 drinking over the whole distribution.
- 111

112 Methods

113 Exposure GWAS and selection of genetic instruments

114	We used the largest GWAS of lifetime smoking index (LSI) (25) and alcohol consumption
115	(drinks per week) (26), avoiding sample overlap with the outcome GWAS, which can bias
116	results. Both GWAS only included participants of European ancestry and with complete
117	genotype and phenotypic data (for relevant smoking and alcohol phenotypes), resulting in
118	462,690 participants from UKBB in the LSI GWAS and 941,280 participants from GSCAN
119	(GWAS and Sequencing Consortium of Alcohol and Nicotine) in the drinks per week GWAS.
120	GWAS adjusted for principal components to further control for population substructure.
121	SNPs (and associations with the relevant exposures) were selected if they reached genome-
122	wide statistical significance ($p \le 5x10^{-08}$) and were independent (i.e., we excluded SNPs in
123	linkage disequilibrium; r ² of 0.001; window of 10,000 kb; European 1000 genomes reference
124	panel). For any palindromic SNPs we tried to infer the positive strand based on allele
125	frequencies, but if this was not possible, these SNPs were excluded. Where a SNP was
126	available for the exposure and not the outcome, we attempted to identify proxy SNPs using
127	LDlink (27) and an LD r^2 threshold of >0.8. After exclusions and identifying any proxies, we
128	searched for the remaining LSI SNPs in the outcome GWAS (118 SNPs for all outcomes) and
129	the remaining alcohol consumption SNPs in the outcome GWAS (70 SNPs for all outcomes).
130	Details of the exposure GWAS, including derivation of the LSI and drinks per week of alcohol
131	are provided in Supplementary Materials Section 1. To summarise, the LSI reflects a
132	combination of smoking related behaviours including smoking status, duration and
133	heaviness, where never smokers have a score of 0. Drinks per week reflects the average
134	number of drinks/glasses consumed per week by participants.

LSI is in standard deviation (SD) units, therefore, in our MR analyses we explore effects per 1

- 136 SD higher LSI. To give context, 1 SD higher LSI value is equivalent to an individual smoking 20
- 137 cigarettes per day for 15 years and stopping 17 years ago or smoking 60 cigarettes a day for
- 138 13 years and stopping 22 years ago. Natural log-transformed drinks per week were used in
- the GWAS, therefore, in our MR analyses we explore effects per 1 SD higher log-
- 140 transformed drinks per week. To give context, in UKBB (the sample used in our one-sample
- 141 MR) 1 SD was equal to 2.14 of the log transformed drinks per week.

142 Outcome GWAS and harmonisation of exposure SNPs

143 We obtained associations of the exposure SNPs with outcomes from the largest GWAS of

144 T2D (28), fasting glucose (29), fasting insulin (29) and glycated haemoglobin (HbA1c) (29).

145 We only used GWAS data including participants of European ancestry, resulting in 148,726

146 cases and 965,732 controls from the Million Veteran Program, DIAMANTE and Biobank

147 Japan for T2D. The continuous traits all used data from the Meta-Analyses of Glucose and

148 Insulin-related traits Consortium (MAGIC), with 209,605 participants with data for fasting

149 glucose, 158,550 with data for fasting insulin and 149,289 with data for HbA1c. GWAS

150 summary statistics for the exposure and outcome were harmonised so that the SNP allele-

151 exposure and SNP allele-outcome associations were in the same direction. Details of these

152 GWAS can be found in Supplementary Materials Section 2. To summarise, the T2D GWAS

153 included cases with a diagnosis of T2D and controls without, fasting glucose was measured

in mmol/l, fasting insulin in pmol/l in serum and HbA1c as a percentage. Therefore, in our

155 MR analyses results are reported as the odds of T2D and the difference in mean fasting

156 glucose (mmol/l), fasting insulin (pmol/l) and HbA1c (NGSP percent or equivalent) per 1 SD

157 higher LSI or log-transformed drinks per week.

158 UK Biobank data for one-sample Mendelian randomisation

- 159 We used data from the UKBB, a large population-based prospective health research
- 160 resource of 503,317 participants (5.5% response of those invited), recruited between 2006
- and 2010, aged between 38 and 73 years and from the UK (30). Further details are included
- 162 in the Supplementary Materials (Section 3 and on the study website
- 163 (www.ukbiobank.ac.uk)). We were only able to assess the effect of drinks per week on T2D
- and HbA1c because the LSI genetic instruments were obtained from UKBB and the glucose
- and insulin measures in UKBB were from non-fasting samples.
- 166 Drinks per week
- 167 The drinks per week phenotype was constructed from responses to questions on the
- 168 average weekly intake of a range of different alcoholic beverages (defined as number of
- 169 glasses they had). Where this information was not available, weekly consumption was
- 170 estimated from measures of average monthly intake (see Supplementary Materials, Section
- 171 4 for further details). Data were natural log-transformed due to being right skewed and
- 172 standardised (1 SD was equal to 2.14 of the log transformed drinks per week).

173 Type 2 diabetes

We derived possible or probable T2D using the Eastwood algorithm (31) (see Supplementary
Materials Section 5). In one-sample MR analyses we excluded individuals who had possible
or probable type 1 diabetes as per the Eastwood algorithm.

177 HbA1c

178 Serum HbA1c (mol/mol) was assayed using five Bio-Rad Variant II Turbo analysers, values

- 179 outside of the reportable range of 15 to 184 mmol/mol, or invalidated for any other reason,
- 180 were excluded (further information can be found at
- 181 <u>https://biobank.ctsu.ox.ac.uk/crystal/ukb/docs/serum_hb1ac.pdf</u>). These analysers used
- 182 high performance liquid chromatography (HPLC) to determine the relative concentration of
- 183 HbA1c in packed red blood cells, from blood samples (approximately 9ml) collected at
- 184 recruitment. Many studies examining continuous traits related to T2D exclude participants
- 185 with a diabetes diagnosis or above thresholds indicative of diabetes. This means that results
- are not necessarily applicable to the whole population from which the study sample is
- drawn and can result in selection bias (32). On the other hand, people with a diagnosis of
- 188 diabetes will have made changes to their lifestyles and/or be on medications that impact
- 189 these continuous traits and associations with them. Therefore, we conducted analyses with
- and without excluding those with possible or probable type 1 or type 2 diabetes using the
- 191 Eastwood algorithm and those who had a HbA1c measure of $\geq 6.5\%$ (or 48 mmol/mol) at
- 192 baseline. Data were natural log-transformed due to being right skewed and standardised (1
- 193 SD was equal to 0.15 log mmol/mol). As UKBB did not collect fasting samples we have not
- 194 conducted one-sample MR on fasting glucose and insulin.

195 Genetic data

- 196 A total of 488,377 participants had genotyped samples. Pre-imputation quality control,
- 197 phasing and imputation are described elsewhere (33) and summarised in the
- 198 Supplementary Materials (Section 6).
- 199 Statistical analysis

- 200 We pre-registered the analysis plan for this study on the Open Science Framework in March
- 201 2021 (<u>https://osf.io/ygucn</u>). All analyses were conducted in R (34) (version 3.6.2).
- 202 Two-sample Mendelian randomisation analyses
- 203 We conducted two-sample MR analyses using the TwoSampleMR package in R (35).
- 204 We used the inverse-variance weighted (IVW) method as our main analysis (36). This fits a
- 205 linear regression model of the mean SNP-outcome value on mean SNP-exposure value
- across all SNPs and constrains the intercept of the regression slope to be zero, with the
- slope providing an unbiased effect estimate under the assumption that there is no
- 208 horizontal pleiotropy (37). Sensitivity analyses used to explore this assumption were done
- using MR-Egger (38), weighted median (39), MR Pleiotropy RESidual Sum and Outlier (MR-
- 210 PRESSO) (40) and Generalised Summary-data-based MR (GSMR) (41) methods.

211 MR Egger is identical to IVW with the exception that the intercept reflects the best fitted 212 regression model and is not constrained to zero (38). The slope provides a causal estimate 213 controlling for potential unbalanced horizontal pleiotropy. As with IVW, this approach is also 214 subject to the Instrument Strength Independent of Direct Effect (InSIDE) assumption, which 215 may be violated if any pleiotropic effects are all via a single factor that is correlated with the 216 association of the genetic instrument with the exposure (i.e., instrument strength). A non-217 null intercept from MR Egger is indicative of unbalanced horizontal pleiotropy and we used 218 the p-value for the intercept to assess this.

The weighted median provides an unbiased causal estimate if no more than 50% of the
weight of the SNPs used in the genetic instrument are influenced by horizontal pleiotropy

(i.e. results may be biased if one single SNP or several SNPs cumulatively contribute 50% of
the weight and are horizontally pleiotropic) (39).

223 MR-PRESSO is used to detect and correct for potential horizontal pleiotropic outliers in the 224 instrument (40). It comprises of three stages to test this. An initial global test assesses 225 whether the total residual sum of squares (RSS) is similar to that expected by chance. Then 226 any outliers are identified by examining the RSS of each SNP. Finally, the extent to which 227 these outliers effect the causal estimate is evaluated by using the distortion test. From this 228 analysis we get an uncorrected and an outlier-corrected causal estimate and we use results 229 from the global and distortion tests to detect horizontal pleiotropy and test for distortion 230 between the estimate before and after correction, respectively. For MR-PRESSO the 231 precision of the p-values is determined by the number of elements to simulate, specified in 232 the model. We used a value of 2,000 for all analyses, except for lifetime smoking on fasting 233 glucose in both main and additional analyses and fasting insulin in the main analyses, where 234 we used 3,000 due to the model being unable to estimate the p-value with the lower value. 235 The GSMR approach allows estimation of a causal effect including SNPs in the instrument 236 that are correlated, by estimating the LD between SNPs from a reference sample (41). The

237 GSMR model also removes outliers which may be associated with confounding factors by

assessing heterogeneity across SNPs, using the heterogeneity in dependent instrument

239 (HEIDI) test, and models the SNP-exposure estimate error which other MR methods do not

240 include.

In addition, we explored between SNP heterogeneity, which might be an indicator of
horizontal pleiotropy or violation of other assumptions, using Cochran's Q, where a p-value
<0.05 may indicate the presence of between SNP heterogeneity. We also assessed

244 heterogeneity between SNPs, whilst adjusting for any horizontal pleiotropy for the MR-245 Egger method, using the Rucker's Q-test, again with a p-value threshold of <0.05. 246 The IVW and MR-Egger methods assume that there is no measurement error in the SNP-247 exposure estimates (39), known as the 'NO Measurement Error' (NOME) assumption. The 248 extent of the NOME assumption violation can be quantified using regression dilution I-249 squared statistics, where a lower value indicates greater violation. An I-squared of less than 250 0.9, indicates that MR-Egger estimates should be interpreted with caution due to regression 251 dilution and where this is the case, we have conducted simulation extrapolation (SIMEX) 252 corrections as a sensitivity analysis. The SIMEX approach is a bias adjustment method which 253 provides an estimate for the case where NOME had been satisfied. We also estimated the 254 mean F-statistic for each analysis, which indicates instrument strength, where a value under 255 10 may indicate a weak instrument (39). 256 Overall, by using these different methods, which make different assumptions, we were able 257 to assess the robustness of evidence for causal effects against violations of the MR 258 assumptions. We were interested in whether there was evidence of causal effects. 259 However, we have previously shown that causal effect estimates when using exposures 260 related to cigarette smoking may be unreliable (42). Therefore, we considered consistency

against the null) across analyses to guide our inference regarding whether or not a causal
effect may be operating, but did not attempt to directly estimate the magnitude of any such
effect (43).

of evidence (e.g., direction of effect estimate, p-value as a measure of strength of evidence

261

Finally, the GWAS used for the outcomes of fasting glucose and fasting insulin adjust for
body mass index (BMI), which can bias our results. Multivariable MR (MVMR) analyses

including BMI can help overcome this issue and provide unbiased estimates of the exposure
of interest (LSI and drinks per week) on the outcome (44) (see Supplementary Materials
Section 7 for further details).

270 One-sample Mendelian randomisation analyses

271 One-sample MR analyses were conducted using the OneSampleMR and Applied 272 Econometrics with R (AER) packages, respectively, in R (45,46). We generated weighted 273 allele genetic risk scores in UKBB for alcohol consumption using the per-allele regression 274 coefficients from each independent genome-wide significant SNP for each exposure as 275 weights and then summing those weighted values (see Supplementary Materials Section 8). 276 We used two-stage least squares regression with adjustment for age, sex, the first 10 277 principal components (PCs) (derived from PC analysis of UKBB genotype data, imputed to a 278 reference set combining UK10K haplotype and Haplotype Reference Consortium [HRC] 279 reference panels), assessment centre and genotyping chip. Two genotyping chips were, the 280 UKBB axiom array (which 90% of participants were genotyped with) and the UK BILEVE 281 array. The latter was used for those in the UK BiLEVE study (47), which was oversampled for 282 smokers, and therefore adjusting for genotyping chip may introduce collider bias. Therefore, 283 we performed analyses with and without adjustment for chip.

284 Ethics

All studies that contributed to the exposure and outcome GWAS used in MR analyses had ethics approval and participant consent for their data to be used in genetic analyses. UKBB (data used in one-sample MR analyses) received ethics approval from the UK National Health Service Research Ethics Committee (11/NW/0382).

289 Data availability

- Access details for the GWAS data used in this study are outlined in Supplementary Table S1.
- 291 UK Biobank data are available through a procedure described at
- 292 <u>http://www.ukbiobank.ac.uk/using-the-resource/.</u>
- 293 Analysis code is available from the University of Bristol's Research Data Repository
- 294 (<u>http://data.bris.ac.uk/data/</u>), at: To be added on publication.

296 Results

297 Two-sample Mendelian randomisation with lifetime smoking as the exposure

298	Mean F-statistics for LSI were all 44.27 (Supplementary Table S2). Figure 1, Figure 2 and
299	Supplementary Table S3 provide the results from the main IVW and all sensitivity analyses
300	of the effects of LSI on outcomes. For T2D, the main IVW result suggested a causal effect of
301	higher LSI on T2D risk (OR per 1SD higher LSI=1.42, 95% CI=1.22 to 1.64). Results from
302	weighted median, PRESSO (with and without outlier correction) and the GSMR sensitivity
303	analyses were consistent with this. By contrast MR-Egger and SIMEX adjusted MR-Egger
304	results were in the opposite direction, though with wide confidence intervals (OR per 1SD
305	higher LSI=0.80, 95% CI=0.46 to 1.41 for MR Egger and OR=0.75, 95% CI=0.43 to 1.31 for
306	SIMEX adjusted MR-Egger). There was also evidence of between SNP heterogeneity
307	(Cochran's Q p-value = 5.42×10^{-66} ; Rucker's Q p-value = 1.10×10^{-62}) and potential bias due to
308	unbalanced horizontal pleiotropy based on the MR-Egger and SIMEX adjusted MR Egger
309	intercepts (p=0.04 and p=0.02, respectively) and the MR-PRESSO global test (p<0.0003).
310	Figure 1. Two-sample Mendelian randomisation results of the potential causal effect of
311	lifetime smoking on type 2 diabetes



Results are the odds ratios (OR) of type 2 diabetes per 1 SD higher lifetime smoking index score, with 95%

314 confidence intervals (CI), noting that 1 SD higher LSI value is equivalent to an individual smoking 20

315 cigarettes per day for 15 years and stopping 17 years ago or smoking 60 cigarettes a day for 13 years and

316 stopping 22 years ago. SNP=single nucleotide polymorphism, IVW=inverse-variance weighted,

317 SIMEX=simulation extrapolation, PRESSO= Pleiotropy RESidual Sum and Outlier, GSMR=Generalised

318 Summary-data-based Mendelian Randomisation

319 Our main IVW analyses also suggested that LSI was not causally related to fasting glucose

320 (difference in mean fasting glucose in mmol/l per 1SD higher LSI=0.003, 95% CI=-0.03 to

321 0.04), fasting insulin (difference in mean fasting insulin in pmol/l per 1SD higher LSI=-0.03,

322 95% CI=-0.07 to 0.02) or HbA1c (difference in mean HbA1c in NGSP percent or equivalent

323 per 1SD higher LSI=0.009, 95% CI=-0.01 to 0.03). Sensitivity analyses were mostly consistent

324 with these results, with the exception of MR-Egger and SIMEX adjusted MR-Egger, where

imprecise estimates suggested that higher LSI might reduce fasting insulin (Figure 2).

326 Additional MVMR analyses accounting for BMI for fasting glucose and fasting insulin were in

327 line with the main IVW results (Supplementary Table S4).

328

329 Figure 2. Two-sample Mendelian randomisation results of the potential causal effect of

330 lifetime smoking on glycaemic traits

Outcome	Method	N SNPs	Effect	95% CI	Р	
Fasting glucose	IVW	118	0.003	-0.03, 0.04	0.87	-
	MR Egger	118	-0.02	-0.18, 0.13	0.75	
	SIMEX	118	-0.04	-0.22, 0.15	0.71	
	Weighted median	118	-0.01	-0.05, 0.03	0.61	
	PRESSO (raw)	118	0.003	-0.03, 0.04	0.87	-
	PRESSO (outlier corrected)	114	-0.008	-0.04, 0.03	0.64	
	GSMR	118	-0.01	-0.04, 0.01	0.36	
Fasting insulin	IVW	118	-0.03	-0.07, 0.02	0.16	-•
	MR Egger	118	-0.2	-0.35, -0.04	0.01	
	SIMEX	118	-0.19	-0.32, -0.06	0.006	• • • • • • • • • • • • • • • • • • •
	Weighted median	118	-0.04	-0.08, 0.008	0.11	
	PRESSO (raw)	118	-0.03	-0.07, 0.01	0.16	
	PRESSO (outlier corrected)	113	-0.03	-0.06, 0.003	0.08	
	GSMR	119	-0.02	-0.05, 0.008	0.16	
HbA1c	IVW	118	0.009	-0.01, 0.03	0.45	-
	MR Egger	118	-0.02	-0.11, 0.08	0.74	
	SIMEX	118	-0.02	-0.11, 0.07	0.62	
	Weighted median	118	0.03	-0.0007, 0.05	0.06	
	PRESSO (raw)	118	0.009	-0.01, 0.03	0.45	+
	GSMR	123	0.01	-0.007, 0.03	0.22	
						-0.4 -0.3 -0.2 -0.1 0 0.1

332 Results are the difference in mean fasting glucose (mmol/l), fasting insulin (pmol/l) and HbA1c (NGSP 333 percent or equivalent) per 1 SD higher lifetime smoking index value, with 95% confidence intervals (CI), 334 noting that 1 SD higher LSI value is equivalent to an individual smoking 20 cigarettes per day for 15 years 335 and stopping 17 years ago or smoking 60 cigarettes a day for 13 years and stopping 22 years ago. 336 SNP=single nucleotide polymorphism, IVW=inverse-variance weighted, SIMEX=simulation extrapolation, 337 PRESSO= Pleiotropy RESidual Sum and Outlier, GSMR=Generalised Summary-data-based Mendelian 338 Randomisation 339 Two-sample Mendelian randomisation with drinks per week as the exposure 340 Mean F-statistics for alcohol consumption were all 31.55 (Supplementary Table S2). Figure 341 3, Figure 4 and Supplementary Table S3 provide the results from the main IVW and all 342 sensitivity analyses of the effects of alcohol consumption on outcomes. For T2D, the main 343 IVW results suggested that alcohol consumption was not causally related to T2D (OR per 1 344 SD higher log-transformed drinks per week=1.04, 95% CI=0.40 to 2.65). Some of the 345 sensitivity analyses were consistent with these results, however, MR-Egger, weighted 346 median and GSMR estimates suggested a potential causal effect of higher drinks per week 347 on T2D risk, but confidence intervals were wide (Figure 3). There was also evidence of between SNP heterogeneity (Cochran's Q p-value = 2.86x10⁻⁸⁹; Rucker's Q p-value = 2.00x10⁻ 348 349 ⁷⁰) and potential bias due to unbalanced horizontal pleiotropy based on the MR Egger intercept (p=0.0005) and the MR-PRESSO global test (p<5x10⁻⁰⁴). 350 351 Figure 3. Two-sample Mendelian randomisation results of the potential causal effect of

drinks per week on type 2 diabetes





Results are the odds ratios (OR) of type 2 diabetes per 1 SD higher log-transformed drinks per week, with
95% confidence intervals (CI). SNP=single nucleotide polymorphism, IVW=inverse-variance weighted,
SIMEX=simulation extrapolation, PRESSO= Pleiotropy RESidual Sum and Outlier, GSMR=Generalised
Summary-data-based Mendelian Randomisation

358 Our main IVW analyses suggested a potential casual effect of higher drinks per week on 359 higher fasting glucose (difference in mean fasting glucose in mmol/l per 1SD higher log-360 transformed drinks per week=0.34, 95% CI=0.09 to 0.59). This was consistent across all 361 sensitivity analyses. However, there was also evidence of between SNP heterogeneity 362 (Cochran's Q p-value = 5.18×10^{-40} ; Rucker's Q p-value = 7.13×10^{-40}) and potential bias due to 363 unbalanced horizontal pleiotropy based on the MR-PRESSO global test ($p < 5x10^{-04}$), but not 364 the MR-Egger intercept (p=0.46). Our main IVW analyses suggested that drinks per week was not causally related to fasting insulin (difference in mean fasting insulin in pmol/l per 365 366 1SD higher LSI=0.08, 95% CI=-0.16 to 0.32) or HbA1c (difference in mean HbA1c in NGSP 367 percent or equivalent per 1SD higher LSI=-0.05, 95% CI=-0.17 to 0.07). Sensitivity analyses 368 were mostly consistent with these results, with the exception of the GSMR estimate 369 suggesting that higher drinks per week might reduce fasting insulin (Figure 4). The effect 370 from the additional MVMR analyses accounting for BMI for fasting glucose was attenuated

- 371 and did not provide evidence of a potentially causal effect. For fasting insulin, the MVMR
- analysis results were in line with the main IVW results (Supplementary Table S4).

373 Figure 4. Two-sample Mendelian randomisation results of the potential causal effect of

374 drinks per week on glycaemic traits

375

Outcome	Method	N SNPs	Effect	95% CI	Ρ	
Fasting glucose	IVW	70	0.34	0.09, 0.59	0.007	· •
	MR Egger	70	0.47	0.05, 0.9	0.03	
	Weighted median	70	0.22	0.03, 0.41	0.03	
	PRESSO (raw)	70	0.34	0.09, 0.59	0.009	•
	PRESSO (outlier corrected)	68	0.17	0.04, 0.31	0.02	
	GSMR	11	0.25	0.1, 0.41	0.001	
Fasting insulin	IVW	70	0.08	-0.16, 0.32	0.53	
	MR Egger	70	0.03	-0.37, 0.42	0.9	
	Weighted median	70	-0.15	-0.37, 0.06	0.16	
	PRESSO (raw)	70	0.08	-0.16, 0.32	0.53	
	PRESSO (outlier corrected)	68	-0.1	-0.26, 0.05	0.2	
	GSMR	10	-0.2	-0.37, -0.03	0.02	
HbA1c	IVW	70	-0.05	-0.17, 0.07	0.45	
	MR Egger	70	-0.02	-0.22, 0.18	0.83	
	Weighted median	70	-0.06	-0.2, 0.08	0.39	
	PRESSO (raw)	70	-0.05	-0.17, 0.07	0.45	
	PRESSO (outlier corrected)	68	-0.1	-0.21, 0.004	0.06	
	GSMR	11	-0.07	-0.18, 0.04	0.23	
						-0.5 0 0.5 1

376 Results are the difference in mean fasting glucose (mmol/l), fasting insulin (pmol/l) and HbA1c (NGSP

377 percent or equivalent) per 1 SD higher log-transformed drinks per week, with 95% confidence intervals

$\mathbf{J}_{\mathbf{J}}$	78 ((CI). SNP=single nucleotide	polymorphism	, IVW=inverse-variance w	veighted, SIMEX=simulat
---------------------------	------	-----------------------------	--------------	--------------------------	-------------------------

- extrapolation, PRESSO= Pleiotropy RESidual Sum and Outlier, GSMR=Generalised Summary-data-based
 Mendelian Randomisation
- 381 One-sample Mendelian randomisation for drinks per week on type 2 diabetes and HbA1c
- 382 Sample characteristics for those UKBB participants included in the one-sample MR analyses
- 383 are shown in Supplementary Table S5.
- Table 1 provides the results from the one-sample MR analyses. Results suggested a causal
- 385 effect of higher drinks per week on T2D risk (OR per 1 SD higher log-transformed drinks per
- 386 week=1.71, 95% CI: 1.24 to 2.36) and on lower HbA1c levels (but only when we excluded
- 387 participants with a possible or probable diabetes diagnosis or HbA1c \geq 6.5%) (difference in
- 388 mean SD of log transformed HbA1c (mol/mol) per 1 SD higher log-transformed drinks per
- week=-0.07, 95% CI: -0.11 to -0.02). Adjusting for chip did not impact our results.

390	Table 1. One-sample Mendelian randomisation results

			Main analysis		Adjusting for ch	ip¹
		N	OR or effect (95% CI)	<i>p</i> -value	OR or effect (95% CI)	<i>p</i> -value
T2D	Excluding participants with type 1 diabetes ²	266,005	1.71 (1.24 to 2.36)	1.30x10 -09	1.70 (1.23 to 2.35)	1.30x10 ⁻⁰⁹
HbA1c	Including participants with diabetes ²	253,995	-0.02 (-0.08 to 0.03)	0.43	-0.02 (-0.08 to 0.03)	0.40
HbA1c	Excluding participants with diabetes ²	242,412	-0.07 (-0.11 to -0.02)	0.002	-0.07 (-0.11 to -0.02)	0.002

391 Results are the odds ratio (OR) for type 2 diabetes per 1 SD higher log-transformed drinks per week or the

392 difference in mean SD of log transformed HbA1c (mol/mol) per 1 SD higher log-transformed drinks per

- 393 week. ¹We ran additional sensitivity analyses adjusting for genotyping chip which is confounded with
- 394 being in the UK Biobank Lung Exome Variant Evaluation (BiLEVE)²Exclusion criteria for diabetes was
- 395 based on having possible or probable type 1 or type 2 diabetes as determined by the Eastwood algorithm
- 396 or those with HbA1c \geq 6.5%.

397 Discussion

398 We found evidence of a possible causal effect of higher LSI values on risk of T2D in our main 399 IVW analysis, but this was not consistent across sensitivity analyses and may be biased due 400 to unbalanced horizontal pleiotropy. Furthermore, the lack of evidence of an effect on the underlying glycaemic traits suggests that we cannot confidently interpret this as a causal 401 402 effect on T2D risk. We found little evidence of a possible causal effect of higher drinks per 403 week on T2D risk, with no effect found for our main IVW analyses in the two-sample MR 404 and inconsistent evidence in our sensitivity analyses. However, the lack of a consistent 405 finding means that we would not interpret this as being evidence of a causal effect. We did 406 observe a possible causal effect of drinks per week on fasting glucose, which was consistent 407 across sensitivity analyses, but this was not supported by analyses with the other underlying 408 glycaemic traits and when accounting for BMI this effect was no longer observed. 409 Additionally, results from our one-sample MR analyses (only examining drinks per week on 410 T2D and HbA1c) suggest that there may be a causal effect of more drinks per week on T2D 411 risk and lower HbA1c levels. These mixed results do not provide strong evidence of causal 412 effects but do suggest that LSI and drinks per week may have some effect on some of these 413 outcomes; however, the explanations for these effects may be complicated, for example, 414 acting through pleiotropic pathways.

Previous studies have largely shown associations using multivariable regression, and potential causal effects using MR, between smoking and T2D risk (10,12,21,22,48) and between higher alcohol consumption and T2D risk (17,18,23,24). However, we note that a previous MR study using a functional variant for alcohol metabolism did not find an effect on T2D (23), in line with our results, suggesting it is unlikely there is an effect of alcohol on

T2D. In addition, our finding with decreased HbA1c in the one-sample MR analyses is in the opposite direction to what we might expect given that higher levels of HbA1c are observed in those with T2D. However, this may be due to the exclusion of individuals with a diagnosis of diabetes, and we do not find an effect in our two-sample MR, so results should be interpreted with caution. Our results suggest that future studies examining risk factors for T2D should triangulate results across different analyses and consider underlying glycaemic traits as outcomes in order to arrive at the correct conclusions.

427 Limitations

428 The key strengths of this study and how this study adds to previous literature is described in 429 the introduction and above. In terms of limitations, we were unable to explore a non-linear 430 effect as recent evidence suggests that current methods for doing so in MR are potentially 431 biased (49). Some observational studies have suggested a J-shaped association between 432 alcohol and coronary heart disease, which T2D is a risk factor for (14–16,19). However, that J-shaped association, even if causal, suggests a linear association across most of the 433 434 distribution. Our one-sample MR analyses in UKBB may be subject to selection bias (50,51). 435 Future studies replicating these analyses in other samples would be useful to examine 436 whether selection bias in UKBB may be an issue here, however our two-sample MR analyses 437 in part overcome this for alcohol but not lifetime smoking where the GWAS was conducted 438 in UK Biobank as well. Our analyses were conducted in samples of European ancestry, due 439 to the data available, so results are not generalisable beyond this group. Finally, it is possible 440 that measurement error in the exposure or outcome could bias our results. This is more likely to be the case for the exposures, which could be subjectively influenced, for example 441 442 misreporting of cigarettes smoked per day, time since cessation or duration of smoking and

443	number of drinks consumed per week. In particular, in UKBB drinks per week is measured
444	based on number of glasses of alcohol consumed and this is similar to the definitions used in
445	the GWAS. This doesn't account for units and glass/drink size can vary, so there is likely
446	variation in how this was reported.
447	Conclusion
448	In summary, we found limited evidence of a possible causal effect of higher lifetime smoking
449	index score and drinks per week score on T2D risk. We found further evidence of a possible
450	causal effect of higher drinks per week on higher fasting glucose. However, overall results
451	were not consistent across analyses and some results may be biased by horizontal
452	pleiotropy. Therefore, we do not find strong evidence of smoking and alcohol influencing
453	risk of T2D. Future research should include triangulation approaches and glycaemic traits to
454	allow for a more in depth understanding of the causal influence of risk factors on T2D.
455	

456 Acknowledgements:

- 457 This research has been conducted using data from UKBB (project ID: 9142), a major
- 458 biomedical database (<u>http://www.ukbiobank.ac.uk/</u>). We would like to thank the research
- 459 participants and employees of 23andMe, inc. for making this work possible. For the purpose
- 460 of open access, the author(s) has applied a Creative Commons Attribution (CC BY) licence to
- 461 any Author Accepted Manuscript version arising from this submission. The type 2 diabetes
- 462 GWAS included data from the Million Veteran Program (MVP), Office of Research and
- 463 Development, Veterans Health Administration, and was supported by the Veterans
- 464 Administration (VA). The authors thank MVP staff, researchers, and volunteers, who have
- 465 contributed to MVP, and especially participants who previously served their country in the
- 466 military and now generously agreed to enroll in the study. (See
- 467 https://www.research.va.gov/mvp/ for more details). The MVP GWAS data was provided
- through dbGaP under accession number phs001672.
- 469 *Funding:* This work was supported in part by the UK Medical Research Council Integrative
- 470 Epidemiology Unit at the University of Bristol (Grant ref: MC_UU_00032/05 and
- 471 MC_UU_00032/07). HMS was supported by the European Research Council (Grant ref:
- 472 758813 MHINT). RCR was supported by Cancer Research UK (grant
- 473 number C18281/A29019). DAL's contribution is supported by the British Heart Foundation
- 474 (CH/F/20/90003 and AA/18/1/34219). MRM was supported by the National Institute for
- 475 Health Research Bristol Biomedical Research Centre. The views expressed in this publication
- are those of the author(s) and not necessarily those of the NHS, the National Institute for
- 477 Health Research or the Department of Health and Social Care.
- 478 **Competing interests:** No competing interests.

- 479 Author contributions: Conceptualization: ASA, MRM, DAL; Methodology: ZER, HMS, MRM,
- 480 DAL; Data Curation: ZER, RCR; Formal Analysis: ZER; Investigation: ZER; Resources: ZER,
- 481 MRM; Writing—Original Draft: ZER; Writing—Review and Editing: ZER, HMS, RCR, ASA, DAL,
- 482 MRM; Supervision: DAL, MRM; Project Administration: ZER; Funding Acquisition: DAL, MRM.

483 References

484	1.	Zoungas S, Arima H, Gerstein HC, Holman RR, Woodward M, Reaven P, et al. Effects
485		of intensive glucose control on microvascular outcomes in patients with type 2
486		diabetes: a meta-analysis of individual participant data from randomised controlled
487		trials. Lancet Diabetes Endocrinol [Internet]. 2017 Jun 1 [cited 2021 Sep 28];5(6):431-
488		7. Available from: http://www.ncbi.nlm.nih.gov/pubmed/28365411
489	2.	Ahmad OS, Morris JA, Mujammami M, Forgetta V, Leong A, Li R, et al. A Mendelian
490		randomization study of the effect of type-2 diabetes on coronary heart disease. Nat
491		Commun [Internet]. 2015 Nov 28 [cited 2021 Sep 28];6(1):7060. Available from:
492		http://www.nature.com/articles/ncomms8060
493	3.	Ray KK, Seshasai SRK, Wijesuriya S, Sivakumaran R, Nethercott S, Preiss D, et al. Effect
494		of intensive control of glucose on cardiovascular outcomes and death in patients with
495		diabetes mellitus: a meta-analysis of randomised controlled trials. The Lancet
496		[Internet]. 2009 May 23 [cited 2021 Sep 28];373(9677):1765–72. Available from:
497		http://www.ncbi.nlm.nih.gov/pubmed/19465231
498	4.	Gan W, Bragg F, Walters RG, Millwood IY, Lin K, Chen Y, et al. Genetic predisposition
499		to type 2 diabetes and risk of subclinical atherosclerosis and cardiovascular diseases
500		among 160,000 Chinese adults. Diabetes [Internet]. 2019 [cited 2021 Sep
501		28];68(11):2155–64. Available from:
502		http://www.ncbi.nlm.nih.gov/pubmed/31399431

503	5.	Lin X. Xu Y	. Pan X. X	(u.J. Ding	Y. Sun X	. et al. Global	. regional	. and national	burden and
505	<u>J</u> .		,		, , , , , , , , , , , , , , , , , , , ,		, , , , , , , , , , , , , , , , , , , ,	, and national	barach ana

- 504 trend of diabetes in 195 countries and territories: an analysis from 1990 to 2025. Sci
- 505 Rep [Internet]. 2020 Dec 8 [cited 2021 Sep 27];10(1):14790. Available from:
- 506 https://www.nature.com/articles/s41598-020-71908-9
- 507 6. Dabelea D, Mayer-Davis EJ, Saydah S, Imperatore G, Linder B, Divers J, et al.
- 508 Prevalence of type 1 and type 2 diabetes among children and adolescents from 2001
- 509 to 2009. JAMA Journal of the American Medical Association [Internet]. 2014 May 7
- 510 [cited 2021 Sep 27];311(17):1778–86. Available from:
- 511 http://jama.jamanetwork.com/article.aspx?doi=10.1001/jama.2014.3201
- 512 7. Apovian CM, Riffenburg KM. Perspectives on the global obesity epidemic [Internet].
- 513 Vol. 24, Current Opinion in Endocrinology, Diabetes and Obesity. 2017 [cited 2021
- 514 Sep 27]. p. 307–9. Available from: http://journals.lww.com/01266029-201710000-
- 515 00002
- 516 8. Xu L, Borges MC, Hemani G, Lawlor DA. The role of glycaemic and lipid risk factors in
- 517 mediating the effect of BMI on coronary heart disease: a two-step, two-sample
- 518 Mendelian randomisation study. Diabetologia [Internet]. 2017 Sep 9 [cited 2021 Oct
- 519 6];60(11):2210–20. Available from: https://link.springer.com/article/10.1007/s00125-
- 520 017-4396-y
- 521 9. Kolb H, Martin S. Environmental/lifestyle factors in the pathogenesis and prevention
 522 of type 2 diabetes. BMC Med [Internet]. 2017 Dec 19 [cited 2020 Nov 26];15(1):131.

523		Available from: http://bmcmedicine.biomedcentral.com/articles/10.1186/s12916-
524		017-0901-x
525	10.	Maddatu J, Anderson-Baucum E, Evans-Molina C. Smoking and the risk of type 2
526		diabetes [Internet]. Vol. 184, Translational Research. NIH Public Access; 2017 [cited
527		2020 Nov 26]. p. 101–7. Available from:
528		http://www.ncbi.nlm.nih.gov/pubmed/28336465
529	11.	Zheng Y, Ley SH, Hu FB. Global aetiology and epidemiology of type 2 diabetes mellitus
530		and its complications [Internet]. Vol. 14, Nature Reviews Endocrinology. Nature
531		Publishing Group; 2018 [cited 2020 Nov 26]. p. 88–98. Available from:
532		http://www.nature.com/articles/nrendo.2017.151
533	12.	Bellou V, Belbasis L, Tzoulaki I, Evangelou E. Risk factors for type 2 diabetes mellitus:
534		An exposure-wide umbrella review of meta-analyses. Nerurkar P V., editor. PLoS One
535		[Internet]. 2018 Mar 20 [cited 2020 Nov 26];13(3):e0194127. Available from:
536		https://dx.plos.org/10.1371/journal.pone.0194127
537	13.	Pan A, Wang Y, Talaei M, Hu FB, Wu T. Relation of active, passive, and quitting
538		smoking with incident diabetes: a meta-analysis and systematic review. Lancet
539		Diabetes and Endocrinology. 2015;3(12):958–67.
540	14.	Griffith C, Bogart D. Alcohol consumption: can we safely toast to our health?
541		[Internet]. Vol. 109, Missouri medicine. Missouri State Medical Association; 2012

542 [cited 2021 Jul 21]. p. 459–65. Available from:

543 http://www.ncbi.nlm.nih.gov/pubmed/23362649

544	15.	O'Keefe JH, Bybee KA, Lavie CJ. Alcohol and Cardiovascular Health. The Razor-Sharp
545		Double-Edged Sword [Internet]. Vol. 50, Journal of the American College of
546		Cardiology. Elsevier; 2007 [cited 2021 Jul 21]. p. 1009–14. Available from:
547		https://www.sciencedirect.com/science/article/pii/S0735109707020074#bib38
548	16.	Chokshi DA, El-Sayed AM, Stine NW. J-shaped curves and public health [Internet]. Vol.
549		314, JAMA - Journal of the American Medical Association. American Medical
550		Association; 2015 [cited 2021 Jul 21]. p. 1339–40. Available from:
551		http://jama.jamanetwork.com/article.aspx?doi=10.1001/jama.2015.9566
552	17.	Koppes LLJ, Dekker JM, Hendriks HFJ, Bouter LM, Heine RJ. Moderate alcohol
553		consumption lowers the risk of type 2 diabetes: A meta-analysis of prospective
554		observational studies [Internet]. Vol. 28, Diabetes Care. American Diabetes
555		Association; 2005 [cited 2021 Jul 21]. p. 719–25. Available from:
556		http://www.ncbi.nlm.nih.gov/pubmed/15735217
557	18.	Baliunas DO, Taylor BJ, Irving H, Roerecke M, Patra J, Mohapatra S, et al. Alcohol as a
558		risk factor for type 2 diabetes: A systematic review and meta-analysis. Diabetes Care
559		[Internet]. 2009 Nov [cited 2021 Jul 21];32(11):2123–32. Available from:
560		http://www.ncbi.nlm.nih.gov/pubmed/19875607
561	19.	Wannamethee SG, Shaper AG, Perry IJ, Alberti KGMM. Alcohol consumption and the
562		incidence of type II diabetes. In: Journal of Epidemiology and Community Health
563		[Internet]. BMJ Publishing Group Ltd; 2002 [cited 2020 Nov 26]. p. 542–8. Available
564		from: http://www.ncbi.nlm.nih.gov/pubmed/12080164

565	20.	Davey Smith (6, Lawlor DA	, Harbord R	, Timpson N	, Dav	I, Ebrahim S.	Clustered
	-							

- 566 environments and randomized genes: a fundamental distinction between
- 567 conventional and genetic epidemiology. Cardon L, editor. PLoS Med [Internet]. 2007
- 568 Dec 11 [cited 2021 Sep 29];4(12):1985–92. Available from:
- 569 https://dx.plos.org/10.1371/journal.pmed.0040352
- 570 21. Yuan S, Larsson SC. A causal relationship between cigarette smoking and type 2
- 571 diabetes mellitus: A Mendelian randomization study. Sci Rep [Internet]. 2019;9(1):1–
- 572 4. Available from: http://dx.doi.org/10.1038/s41598-019-56014-9
- 573 22. Yuan S, Larsson SC. An atlas on risk factors for type 2 diabetes: a wide-angled
- 574 Mendelian randomisation study. Diabetologia [Internet]. 2020 Nov 8 [cited 2020 Nov
- 575 26];63(11):2359–71. Available from: http://link.springer.com/10.1007/s00125-020-
- 576 05253-x
- 577 23. Holmes M V., Dale CE, Zuccolo L, Silverwood RJ, Guo Y, Ye Z, et al. Association
- 578 between alcohol and cardiovascular disease: Mendelian randomisation analysis based
- 579 on individual participant data. BMJ (Online) [Internet]. 2014;349(July):1–16. Available
- 580 from: http://dx.doi.org/doi:10.1136/bmj.g4164
- 581 24. Lu T, Nakanishi T, Yoshiji S, Butler-Laporte G, Greenwood CMT, Richards JB. Dose-
- 582 dependent Association of Alcohol Consumption With Obesity and Type 2 Diabetes:
- 583 Mendelian Randomization Analyses. J Clin Endocrinol Metab. 2023 Nov
- 584 17;108(12):3320–9.

585	25.	Wootton RE	. Richmond RC	. Stuiifzand BG	. Lawn RB	. Sallis HM	. Tavlor GMJ	. et al.
000					,	, canno i nivi,	,	,

- 586 Evidence for causal effects of lifetime smoking on risk for depression and
- 587 schizophrenia: a Mendelian randomisation study. Psychol Med [Internet]. 2019 Nov 6
- 588 [cited 2020 Aug 18];1–9. Available from:
- 589 https://www.cambridge.org/core/product/identifier/S0033291719002678/type/jour
 590 nal article
- 591 26. Liu M, Jiang Y, Wedow R, Li Y, Brazel DM, Chen F, et al. Association studies of up to
- 592 1.2 million individuals yield new insights into the genetic etiology of tobacco and
- 593 alcohol use. Nat Genet [Internet]. 2019 Feb 14 [cited 2020 Jul 1];51(2):237–44.
- 594 Available from: http://www.nature.com/articles/s41588-018-0307-5
- 595 27. Machiela MJ, Chanock SJ. LDlink: A web-based application for exploring population-
- 596 specific haplotype structure and linking correlated alleles of possible functional
- 597 variants. Bioinformatics [Internet]. 2015 Nov 1 [cited 2020 Nov 25];31(21):3555–7.
- 598 Available from: http://www.ncbi.nlm.nih.gov/pubmed/26139635
- 599 28. Vujkovic M, Keaton JM, Lynch JA, Miller DR, Zhou J, Tcheandjieu C, et al. Discovery of
- 600 318 new risk loci for type 2 diabetes and related vascular outcomes among 1.4 million
- 601 participants in a multi-ancestry meta-analysis. Nature Genetics 2020 52:7 [Internet].
- 602 2020 Jun 15 [cited 2022 Dec 16];52(7):680–91. Available from:
- 603 https://www.nature.com/articles/s41588-020-0637-y
- 604 29. Chen J, Spracklen CN, Marenne G, Varshney A, Corbin LJ, Luan J, et al. The trans-
- ancestral genomic architecture of glycemic traits. Nature Genetics 2021 53:6

606	[Internet	. 2021 May	/ 31	cited 2022 Dec 16];53(6	5):840–60. Available from:
-----	-----------	------------	------	-------------------	--------	----------------------------

- 607 https://www.nature.com/articles/s41588-021-00852-9
- 30. Sudlow C, Gallacher J, Allen N, Beral V, Burton P, Danesh J, et al. UK Biobank: An Open
- 609 Access Resource for Identifying the Causes of a Wide Range of Complex Diseases of
- 610 Middle and Old Age. PLoS Med. 2015 Mar 31;12(3):e1001779.
- 611 31. Eastwood S v., Mathur R, Atkinson M, Brophy S, Sudlow C, Flaig R, et al. Algorithms
- 612 for the Capture and Adjudication of Prevalent and Incident Diabetes in UK Biobank.
- 613 PLoS One [Internet]. 2016 Sep 1 [cited 2022 Sep 20];11(9):e0162388. Available from:
- 614 https://journals.plos.org/plosone/article?id=10.1371/journal.pone.0162388
- 615 32. Delgado-Rodríguez M, Llorca J. Bias. J Epidemiol Community Health (1978).
- 616 2004;58(8):635–41.
- 617 33. Bycroft C, Freeman C, Petkova D, Band G, Elliott LT, Sharp K, et al. The UK Biobank

618 resource with deep phenotyping and genomic data. Nature. 2018 Oct

- 619 10;562(7726):203–9.
- 620 34. R Core Team. R: A language and environment for statistical computing. R Foundation
 621 for Statistical Computing, Vienna, Austria; 2016.
- 622 35. Hemani G, Zheng J, Wade KH, Laurin C, Elsworth B, Burgess S, et al. MR-Base: a
- 623 platform for systematic causal inference across the phenome using billions of genetic
- 624 associations. bioRxiv [Internet]. 2016 [cited 2017 Mar 26];078972. Available from:
- 625 http://biorxiv.org/content/early/2016/12/16/078972

626	36.	Burgess S, Butterworth A, Thompson SG. Mendelian Randomization Analysis With
627		Multiple Genetic Variants Using Summarized Data. Genet Epidemiol [Internet]. 2013
628		Nov [cited 2024 Apr 29];37(7):658. Available from: /pmc/articles/PMC4377079/
629	37.	Burgess S, Butterworth A, Thompson SG. Mendelian randomization analysis with
630		multiple genetic variants using summarized data. Genet Epidemiol [Internet]. 2013
631		Nov [cited 2020 Jul 15];37(7):658–65. Available from:
632		http://www.ncbi.nlm.nih.gov/pubmed/24114802
633	38.	Bowden J, Davey Smith G, Burgess S. Mendelian randomization with invalid
634		instruments: Effect estimation and bias detection through Egger regression. Int J
635		Epidemiol. 2015;44(2):512–25.
636	39.	Bowden J, Davey Smith G, Haycock PC, Burgess S. Consistent Estimation in Mendelian
637		Randomization with Some Invalid Instruments Using a Weighted Median Estimator.
638		Genet Epidemiol [Internet], 2016 May:40(4):304–14, Available from:
638		Genet Epidemiol [Internet]. 2016 May;40(4):304–14. Available from:
638 639		Genet Epidemiol [Internet]. 2016 May;40(4):304–14. Available from: http://www.ncbi.nlm.nih.gov/pubmed/27061298
638 639 640	40.	Genet Epidemiol [Internet]. 2016 May;40(4):304–14. Available from: http://www.ncbi.nlm.nih.gov/pubmed/27061298 Verbanck M, Chen CY, Neale B, Do R. Detection of widespread horizontal pleiotropy
638 639 640 641	40.	Genet Epidemiol [Internet]. 2016 May;40(4):304–14. Available from: http://www.ncbi.nlm.nih.gov/pubmed/27061298 Verbanck M, Chen CY, Neale B, Do R. Detection of widespread horizontal pleiotropy in causal relationships inferred from Mendelian randomization between complex
638 639 640 641 642	40.	Genet Epidemiol [Internet]. 2016 May;40(4):304–14. Available from: http://www.ncbi.nlm.nih.gov/pubmed/27061298 Verbanck M, Chen CY, Neale B, Do R. Detection of widespread horizontal pleiotropy in causal relationships inferred from Mendelian randomization between complex traits and diseases. Nat Genet. 2018 May 23;50(5):693–8.
638 639 640 641 642	40.	Genet Epidemiol [Internet]. 2016 May;40(4):304–14. Available from: http://www.ncbi.nlm.nih.gov/pubmed/27061298 Verbanck M, Chen CY, Neale B, Do R. Detection of widespread horizontal pleiotropy in causal relationships inferred from Mendelian randomization between complex traits and diseases. Nat Genet. 2018 May 23;50(5):693–8.
638 639 640 641 642 643	40.	Genet Epidemiol [Internet]. 2016 May;40(4):304–14. Available from: http://www.ncbi.nlm.nih.gov/pubmed/27061298 Verbanck M, Chen CY, Neale B, Do R. Detection of widespread horizontal pleiotropy in causal relationships inferred from Mendelian randomization between complex traits and diseases. Nat Genet. 2018 May 23;50(5):693–8. Zhu Z, Zheng Z, Zhang F, Wu Y, Trzaskowski M, Maier R, et al. Causal associations
638 639 640 641 642 643 644	40.	Genet Epidemiol [Internet]. 2016 May;40(4):304–14. Available from: http://www.ncbi.nlm.nih.gov/pubmed/27061298 Verbanck M, Chen CY, Neale B, Do R. Detection of widespread horizontal pleiotropy in causal relationships inferred from Mendelian randomization between complex traits and diseases. Nat Genet. 2018 May 23;50(5):693–8. Zhu Z, Zheng Z, Zhang F, Wu Y, Trzaskowski M, Maier R, et al. Causal associations between risk factors and common diseases inferred from GWAS summary data. Nat

646	42.	Taylor AE, Davies NM, Ware JJ, Vanderweele T, Smith GD, Munafò MR. Mendelian
647		randomization in health research: Using appropriate genetic variants and avoiding
648		biased estimates. Econ Hum Biol. 2014 Mar 1;13(1):99–106.
649	43.	Sterne JA, Davey Smith G. Sifting the evidence-what's wrong with significance tests?
650		BMJ [Internet]. 2001 Jan 27 [cited 2021 Jul 28];322(7280):226–31. Available from:
651		http://www.ncbi.nlm.nih.gov/pubmed/11159626
652	44.	Gilbody J, Borges MC, Smith GD, Sanderson E. Multivariable MR can mitigate bias in
653		two-sample MR using covariable-adjusted summary associations. medRxiv [Internet].
654		2022 Jul 19 [cited 2024 Jul 9];2022.07.19.22277803. Available from:
655		https://www.medrxiv.org/content/10.1101/2022.07.19.22277803v1
656	45.	Palmer T, Spiller W, Sanderson E. https://github.com/remlapmot/OneSampleMR,
657		https://remlapmot.github.io/OneSampleMR/ 2023. OneSampleMR: One Sample
658		Mendelian Randomization and Instrumental Variable Analyses.
659	46.	Kleiber C, Zeileis A. Applied Econometrics with R. New York.: Springer-Verlag; 2008.
660	47.	Wain L V, Shrine N, Miller S, Jackson VE, Ntalla I, Artigas MS, et al. Novel insights into
661		the genetics of smoking behaviour, lung function, and chronic obstructive pulmonary
662		disease (UK BiLEVE): a genetic association study in UK Biobank. Lancet Respir Med.
663		2015 Oct 1;3(10):769–81.
664	48.	Larsson SC, Burgess S. Appraising the causal role of smoking in multiple diseases: A
665		systematic review and meta-analysis of Mendelian randomization studies.

666	EBioMedicine [Internet]. 2022 Aug 1 [cited 2022 Dec 20];82. Available from:
-----	---

- 667 http://www.thelancet.com/article/S2352396422003358/fulltext
- 668 49. Wade KH, Hamilton FW, Carslake D, Sattar N, Davey Smith G, Timpson NJ. Challenges
- 669 in undertaking nonlinear Mendelian randomization. Obesity [Internet]. 2023 Dec 1
- 670 [cited 2024 Jul 16];31(12):2887–90. Available from:
- 671 https://onlinelibrary.wiley.com/doi/full/10.1002/oby.23927
- 50. Tyrrell J, Zheng J, Beaumont R, Hinton K, Richardson TG, Wood AR, et al. Genetic
- 673 predictors of participation in optional components of UK Biobank. Nat Commun
- 674 [Internet]. 2021 Dec 9 [cited 2021 Apr 9];12(1):886. Available from:
- 675 http://www.nature.com/articles/s41467-021-21073-y
- 676 51. Fry A, Littlejohns TJ, Sudlow C, Doherty N, Adamska L, Sprosen T, et al. Comparison of
- 677 Sociodemographic and Health-Related Characteristics of UK Biobank Participants with
- Those of the General Population. Am J Epidemiol. 2017 Nov 1;186(9):1026–34.